https://spectrumlocalnews.com/nys/central-ny/news/2021/07/01/johnson-johnson-covid-vaccine-youth-kids-
Johnson & Johnson plans to begin a study of its single-dose COVID-19 vaccine in children as young as 12 years old by this fall, a spokesperson for the company said at a symposium hosted by Johns Hopkins University and the University of Washington on Wednesday.
Macaya Douoguih, head of clinical development and medical affairs for vaccines at Janssen, said the pharmaceutical company will use results from its Phase 2a trials — which tested the COVID-19 vaccine in a cohort of adolescents aged 16 and 17 — to inform its trial in the younger population.
“As we all know, the pandemic has had a profound impact on children and adolescents,” Douoguih said in part. “We are focused on the critical work needed to make our single-dose COVID-19 vaccine equitably accessible for all age groups.” Preliminary data from the Phase 2a study will be made publicly available in the near future, she added. The company currently has four adolescent studies planned, the first of which will consist of individuals aged 12-17 years old, which will kick off some time this fall.
Pending preliminary results from that study, Johnson & Johnson hopes to conduct two-part research in children aged 2-11 years old, starting with those aged 6 and up. A third study would test children aged 0-2 years old, with a fourth and final study looking at the vaccine’s efficacy in immunocompromised and high-risk children aged 1-17 years old. In total, the company expects upwards of 4,500 participants of all ages in the upcoming trials.
= new reply since forum marked as read
